{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-061104","form_type":"8-K","ticker":"RANI","cik":"0001856725","company_name":"Rani Therapeutics Holdings, Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.135421+00:00","generated_at":"2026-06-08T11:00:45.147555+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Rani Therapeutics Q3 net loss $18.3M, cash $60.5M, CEO salary cut to $100k, workforce reduced 25%","bullets":["Net loss $18.3M in Q3 2023 vs $16.2M in Q3 2022; R&D spend $11.2M, cash burn extends runway into 2025.","CEO Talat Imran salary reduced from $520k to $100k through 2024 or until $50M is raised.","Strategic prioritization: discontinue RT-101, pause RT-105/RT-110, workforce cut ~25%.","RT-102 Phase 2 starts year-end 2023; RT-111 Phase 1 topline expected Q1 2024; RaniPill HC Phase 1-ready 2H 2024.","RaniPill HC achieved >90% drug delivery success in preclinical studies with adalimumab and interleukin."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-061104","json":"https://secwatch.observer/filing/0000950170-23-061104.json","markdown":"https://secwatch.observer/filing/0000950170-23-061104.md","text":"https://secwatch.observer/filing/0000950170-23-061104.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023061104/0000950170-23-061104-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023061104/rani-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T11:00:45.147555+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ca9d058a0effbc3c5704e32f0d33c3c3d04b092b","claim":"Rani Therapeutics Holdings, Inc. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 8, 2023, Rani Therapeutics Holdings, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023061104/0000950170-23-061104-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}